Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma.

ABSTRACT: After unprecedented successes in B-cell malignancies, chimeric antigen receptor T cells have recently been investigated for the treatment of multiple myeloma. Chimeric antigen receptor targeting T cells B-cell maturation antigen (BCMA) on malignant plasma cells have led to impressive clinical responses in recent trials. However, BCMA-negative relapses have been observed, supporting the need for complementary treatment strategies. Here, we explored the feasibility of targeting CD138 (syndecan-1), a surface marker expressed on both normal and malignant plasma cells. We showed that T cells from both healthy donors and from multiple myeloma patients, when transduced with a CD138-specific chimeric antigen receptor, can eliminate tumor cell lines and primary myeloma cells both in vitro and in vi

SUBMITTER: Sun C 

PROVIDER: S-EPMC6481321 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature